Communicating clinical trial information about cancer drug products to patients and healthcare professionals: review of patient-reported outcome messaging. [PDF]
BMJ OncolShahraz S +8 more
europepmc +1 more source
Patient-Reported Outcomes From LIBRETTO-431: First-Line Selpercatinib Versus Chemotherapy With Pembrolizumab in <i>RET</i> Fusion-Positive NSCLC. [PDF]
JTO Clin Res RepZhou C +13 more
europepmc +1 more source
Mechanism of and research progress on alterations in the RET gene in thyroid cancer (Review). [PDF]
Mol Med RepWei M, Wang R, Qian J, Fang Q, Tao J.
europepmc +1 more source
An emerging melody composed of the notes from structural variants - Comment on 'The fusion characteristics of RET fusion in pan-cancer among the Chinese population: A comprehensive genomic analysis' by Chen et al. [PDF]
Transl OncolWu L, Zhou Q, Lu C.
europepmc +1 more source
Acute severe hypocalcaemia after initiation of a selective RET-inhibitor in medullary thyroid cancer. [PDF]
Endocr OncolCheng L +7 more
europepmc +1 more source
Investigating perceived stress and pain reduction following brief Reiki sessions in high-stress communities: an exploratory study. [PDF]
Front PsycholMcCutcheon H, Habiya SK.
europepmc +1 more source
LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive (RET+) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC. [PDF]
Lung Cancer (Auckl)Lee ATM, Ou SI.
europepmc +1 more source
Long-term safety of selpercatinib for Rearranged during transfection (RET)-activated advanced solid tumors in LIBRETTO-001: differing patterns of adverse events over time. [PDF]
OncologistRaez LE +5 more
europepmc +1 more source